

ELCC 2021 VIRTUAL INDUSTRY SATELLITE SYMPOSIUM

A European Multidisciplinary Perspective on Evolving Treatment Practices in *EGFRm* NSCLC



Thursday 25 March 2021 (Channel 3)
16:10–17:40 (CET)

All recordings will be available for on-demand viewing until Tuesday 30 March 2021

EGFR Mutation Testing in Patients with Resectable NSCLC: Challenges and Considerations

John Gosney

Optimising the Patient Journey in Resectable *EGFRm* NSCLC: A Surgeon's Point of View

Ehab Bishay

Improving Prognosis in Patients With Resected *EGFRm* NSCLC: A Role for Adjuvant EGFR-TKIs

Margarita Majem

First-Line EGFR-TKIs to Improve Patient Outcomes in Advanced *EGFRm* NSCLC

Maurice Pérol

Audience Q&A and Panel Discussion

Chaired by Maurice Pérol



Maurice Pérol (Chair)

Centre Léon Bérard,
Lyon,
France



John Gosney

Liverpool University
Hospitals, Liverpool,
UK



Ehab Bishay

University Hospital Birmingham,
Queen Elizabeth Hospital,
Birmingham, UK



Margarita Majem

Hospital de la Santa Creu i
Sant Pau, Barcelona,
Spain

AstraZeneca's Commitment to Sustainability



\$15.5 million

invested in environmental
efficiency projects in 2019
(NRRGG fund)



CPD A Lists

One of three companies
worldwide to achieve double
A listing for Climate Change
and Water Security for four
consecutive years



62% of our power

is sourced or
generated from
renewable sources



100% of API

(Active Pharmaceutical
Ingredient) discharges
from AstraZeneca sites
were assessed as safe



18% reduction

in our water use
since 2015



**25% of our
vehicles**

in Europe, North America
or Japan are hybrid or
electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's commitment to sustainability at our website.